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Abstract
Background: Bivariate random effects meta-analysis of diagnostic tests is becoming a well
established approach when studies present one two-by-two table or one pair of sensitivity and
specificity. When studies present multiple thresholds for test positivity, usually meta-analysts
reduce the data to a two-by-two table or take one threshold value at a time and apply the well
developed meta-analytic approaches. However, this approach does not fully exploit the data.
Methods: In this paper we generalize the bivariate random effects approach to the situation where
test results are presented with k thresholds for test positivity, resulting in a 2 by (k+1) table per
study. The model can be fitted with standard likelihood procedures in statistical packages such as
SAS (Proc NLMIXED). We follow a multivariate random effects approach; i.e., we assume that each
study estimates a study specific ROC curve that can be viewed as randomly sampled from the
population of all ROC curves of such studies. In contrast to the bivariate case, where nothing can
be said about the shape of study specific ROC curves without additional untestable assumptions,
the multivariate model can be used to describe study specific ROC curves. The models are easily
extended with study level covariates.
Results: The method is illustrated using published meta-analysis data. The SAS NLMIXED syntax
is given in the appendix.
Conclusion: We conclude that the multivariate random effects meta-analysis approach is an
appropriate and convenient framework to meta-analyse studies with multiple threshold without
losing any information by dichotomizing the test results.
Background
Meta-analysis of diagnostic accuracy studies depends on
the type of data that is available from different studies.
The most frequently reported measures of diagnostic test
accuracy are sensitivity and specificity or a two by two
table, i.e. with a single threshold value. Meta-analytic
methodologies for such kind of data have been developed
to summarize sensitivity and specificity separately or
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[1-6]. In recent years the bivariate random effects meta-
analysis of diagnostic tests has become a well established
approach, which can be fitted in many statistical packages
[1,2]. The bivariate approach has many advantages over
separate random effects meta-analysis of sensitivity and
specificity and the traditional summary receiver operating
characteristics (SROC) method of Littenberg and Moses
[1,2,4]. Besides it is flexible to derive different outcome
measures, such as overall sensitivity and/or specificity,
diagnostic odds ratio and SROC curves, from the esti-
mated parameters.
In this article we consider the situation where diagnostic
results for the test under evaluation are reported in three
or more categories; for example, disease severity classified
as malignant, suspect or benign. One straightforward
approach often followed in practice is to dichotomize the
test results into two categories and apply the well devel-
oped bivariate methods separately for each of the thresh-
olds. When data is presented for many thresholds, a ROC
can be calculated per study, and meta-analytic methods
have been developed to derive a SROC from them [7-9].
Poon [10] discusses a latent normal distribution model
for analysing ordinal responses with applications in meta-
analysis. This model can be applied to multiple threshold
diagnostic meta-analysis data. However, this paper only
considered fixed effect modeling. Bipat et al [11] discussed
a multivariate random-effects approach for meta-analysis
of cancer staging. They assumed the correlations between
different cancer stages to be independent, i.e. SROC
curves can not be derived from their model. Specifically
for diagnostic accuracy studies, Dukic et al [12] discussed
both ordinal regression and hierarchical approaches
based on latent variable modeling.
The above approaches are no direct extensions of the now-
adays popular bivariate meta-analysis approach for the
one threshold case. The aim of this article is to generalize
this approach to the situation where test results are pre-
sented using more than one threshold or in more than
two categories. Not necessarily in all studies the same
number of categories is presented, however, in this article
we focus on the case where the number of categories is
equal across studies and we discuss how our approach can
accommodate studies reported with unequal number of
thresholds. Our approach can be implemented in stand-
ard statistical packages. In the methods section we briefly
review the bivariate random effects approach, and we
introduce the multivariate approach to meta-analyse stud-
ies that report test results with more than one threshold.
We illustrate the methods using published meta-analysis
data and end with a discussion.
Methods
The bivariate random effects (BREM) approach
For the situation where each study presents one pair of
sensitivity and specificity with corresponding standard
errors, the bivariate meta-analysis approach [13] has
become a well established method [1,2,14]. The approach
preserves the two-dimensional nature of the original data
taking into account the between-studies correlation of
sensitivity and specificity. It can be seen as an improve-
ment on the method of Littenberg and Moses [4], which
has been the standard method to construct a SROC for
more than a decade.
In this section first we will introduce the bivariate random
effects model (BREM) in its standard form. Subsequently
we will derive another form of the model, which starts
from a model for study specific ROCs and has a different
parametrization. This formulation of the model is the nat-
ural one to generalize to the case where we have two or
more pairs of specificity and sensitivity per study. This for-
mulation also sheds more light on the interpretation of
SROCs, which is problematic in the case where only one
pair of sensitivity and specificity is available.
For study i, denote ξi = logit(1 - specificityi) and ηi =
logit(sensitivityi). Let x1i be the number of true positives, n1i
the total number of diseased subjects, x0i the number of
false positives and n0i the total number of non-diseased
subjects. Then the observed sensitivity and specificity for
a given study i are x1i/n1i and (n0i -x0i)/n0i respectively.
Note that the underlying sensitivity and specificity tend to
be negatively correlated across studies because of explicit
or implicit differences in the thresholds. Therefore ξi andηi will tend to be positively correlated.
Between-studies variability
The between-studies model [1] is given by:
The bivariate distribution of true logit transformed sensi-
tivities and 1-specificities can be characterized by different
lines. Back transforming such a line by taking the inverse
logit gives a SROC. Since there are several reasonable
choices for lines characterizing a bivariate normal distri-
bution, several types of SROCs are possible. For example,
a straightforward choice would be the regression of η on
ξ. However, since the roles of ξ (specificity) and η (sensi-
tivity) are interchangeable, the regression line of ξ on η is
an evenly reasonable choice. The method of Littenberg
and Moses chooses the regression line of D = η-ξ on S = η
+ ξ. Table 1 gives an overview of 5 different choices as dis-
tinguished by Arends et al [2].
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BMC Medical Research Methodology 2009, 9:73 http://www.biomedcentral.com/1471-2288/9/73The different SROCs can be vastly different in applica-
tions, see for instance Arends et al [2] and the data exam-
ples. The BREM approach as introduced by Reitsma et al
[1] and discussed by Arends et al [2] does not assume any-
thing about study specific curves. The method simply
leads to an estimated underlying bivariate distribution of
the true sensitivities and specificities as reported by the
different studies included in the meta-analysis. This
means that the chosen SROC does not necessarily corre-
spond with the true curves of the studies. The true study
specific curves might have a substantially different shape,
and the SROC cannot be interpreted as a kind of average
or overall ROC representative for the ROCs of the differ-
ent studies. There might even be no study specific curves
at all, in case the diagnostic test cannot be thought of as a
continuous test. However, this does not mean that the
analysis does not make sense in this case, since the exist-
ence of study specific ROC curves is not assumed by the
method. In the remainder of this section we introduce a
new formulation of the BREM, which starts with the study
specific ROCs. This will make clear under which extra
assumption the BREM describes the distribution of study
specific ROCs and the calculated SROC can be considered
to be a real overall SROC.
Suppose that in the (ξ, η) space the study specific ROC
curves are straight lines with a common slope β. The lines
of the different studies then only differ in level, character-
ised by the intercept αi for study i:
We assume that the αi's are normally distributed with
mean  and variance . The observations consist of an
estimate ( , ) of one pair (ξi, ηi) per study. To be able
to estimate the parameters, we have to assume a model
that describes how these pairs arise across studies. A
straightforward assumption is that the ξi values are drawn
from a normal distribution with mean  and variance
. This leads to the following marginal model for (ξi,
ηi):
This model is just the same as (1), only with a different
parametrization. However, the number of parameters is
one more, which means that one of them is unidentifia-
ble. To make the model identifiable, we need a further
assumption on how the ξi's in the different studies are
selected. For instance we could assume that σαξ is zero.
This means that the individual investigators, in selecting
their ξi value, are not lead by the level of their line. How-
ever it is perfectly conceivable that an investigator who
happens to have a ROC that is relatively low, tends to
choose a relatively high value for his ξi if a high sensitivity
is preferred, or just a relatively low value of ξi if high spe-
cificity is preferred.
If we assume that the correlation between αi and ξi is zero,
it can be seen that β is given by the slope of the regression
line of η on ξ. In this case the η on ξ type SROC is the true
SROC in the sense that it really can be interpreted as such.
In the (ξ, η) space it is just the average line over the pop-
ulation of studies, in the ROC space it can be interpreted
as a kind of median ROC.
Another assumption could be that the correlation
between η and α is zero. This means that we assume
 and therefore the correlation between α
and ξi is given by ραξ = -σα/(βσξ). The slope, then, is rewrit-
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Table 1: Different choices of summary lines as resulting from the BREM:y = α + βx where y = logit(sensitivity) and x = logit(1-
specificity). []
Parameter Type of regression line
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BMC Medical Research Methodology 2009, 9:73 http://www.biomedcentral.com/1471-2288/9/73ten as , which is the slope of the regression
of ξ on η. Thus under this assumption the ξ on η type
SROC is the real one.
More general, we could assume that some linear combina-
tion aξ + bη of ξ and η is not correlated to α, for some
value of a and b. We have already seen that if a = 1 and b
= 0, the η on ξ type SROC is the correct one. If a = 0 and
b = 1, then the ξ on η type is the correct one. If we assume
a = b = 1, then one can check that β is equal to the slope
of the regression of D = η- ξ on S = η + ξ, and the Litten-
berg & Moses type SROC is the correct one. One can also
check that the assumption a = β and b = 1 leads to the Rut-
ter & Gatsonis (R&G) type SROC. The slope of their
method is the geometric average of the η on ξ and ξ on η
regression line, that is, their regression line always lies in
between the two curves. For a detailed discussion we refer
to Arends et al [2]
Generally, the 5 SROCS only coincide in the very degener-
ate case where the between-studies variances of sensitivity
and specificity are equal and the correlation is one. If only
the between-studies variances of sensitivity and specificity
are equal then the three methods (D on S, R&G and Major
axis) lead to the same SROC curve. Note that all choices of
SROC curves in Table 1, except the R&G, can possibly give
an improper SROC curve that runs from (TPR = 1, FPR =
1) to (TPR = 0, FPR = 0) if one of the following situation
occurred. However, the chance that this occurs in practice
is very unlikely.
1. The η on ξ, ξ on η and major axis methods give an
improper SROC curve if and only if sensitivity and
specificity are positively correlated.
2. The D on S method give an improper SROC curve if
and only if σξη < -  and σξη > -  or σξη > -  and
σξη < - . In either cases sensitivity and specificity are
positively correlated.
Notice that the R&G method always yields a proper SROC
because it implies that the slope parameter is always pos-
itive, being equal to the ratio of the between studies stand-
ard deviations of sensitivity and specificity. It is
remarkable that the R&G SROC can be calculated from
two simple univariate meta-analyses on the sensitivities
and specificities separately. This is an advantage since no
bivariate modeling is needed at all, but it might also ques-
tion its value because apparently it does not use the possi-
ble correlation between sensitivity and specificity. We
conclude that in the situation where we have only one
pair of sensitivity and specificity per study a calculated
SROC can only be interpreted as a real overall ROC under
an untestable assumption. The assumption is especially
sensitive when the differences among the estimated
between-studies variances and covariance of sensitivity
and specificity are large. This issue seems to have been
overlooked in the literature. In a recent letter in Biostatis-
tics Chu and Guo [15] claim that the SROC given by Har-
bord et al [14] and Rutter and Gatsonis [6] are "are
incorrect and potentially misleading". Chu and Guo
assume that the η on ξ type is the "real" SROC, but they
forget that this one is based on an untestable assumption
too. However, the situation changes as soon as more pairs
of sensitivity and specificity are available per study.
Within-study variability
The within-study variability can be modeled using an
approximate normal distribution [1,2] or a binomial dis-
tribution [2,14,16]. Hamza et al [17,18] compared in
extensive simulation experiments the binomial and
approximate normal within-study models, and showed
that in general the performance of the binomial within-
study model is much better. Chu and Cole [16] also
showed similar results using a selected number of simula-
tions. Therefore in this paper we restrict to the binomial
within-study model. For the approximate approach we
refer to [1,2].
The within-study model is based on the binomial distri-
bution of the number of false positive (x0i) and true posi-
tive (x1i) test results. More specifically we assume:
The ξi and ηi = αi + βξi are the true logit transformed (1-
specificity) and sensitivity from (2). The bivariate model
given by (2-4) can be fitted using generalized linear mixed
model procedures in standard statistical packages, such as
the SAS procedure NLMIXED, STATA gllamm or the R/S-
Plus program nlme.
Multivariate random effects meta-analysis (MREM)
In this section we consider studies where a single test is
administered and the results are reported using J - 1
thresholds or, equivalently, with J ordered categories; see
for example references [19,22] and table 2. Let the
number of non-diseased and diseased patients with test
result in category j from the ith study be given by x0ij and
x1ij, respectively. The total number of non-diseased and
β σ σα αξ= − 2 /
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and , respectively. For any given threshold j
sensitivity and specificity are calculated by 
and  respectively. For example, from
table 2, if we consider j = 2, i.e. malignant and suspect as
test positive, sensitivity = (xi1 + xi2)/n1i and specificity = x0i3/
n0i.
The model
Let the true logit transformed 1 - specificity and sensitivity
for a given threshold j be denoted by ξij and ηij respec-
tively, where ξij's and ηij's are ordered in the j index. We
assume a hierarchical model that is a direct generalization
of model (2-3). In contrast to the one threshold case
(bivariate approach), when we have more than one
threshold (multiple points per study), the SROC curve is
identifiable. The between and within-study models are
given as follows:
Between-studies model
1. Model for the relation between ξij and ηij:
Within a study we assume a linear relation with com-
mon slope β and study specific intercept αi.
The parameters  and β determine the summary ROC
curve. Note that β is an asymmetry parameter. If β = 1
then the curve is symmetric around the line of equal
sensitivity and specificity. We could also allow β to
vary across studies and assume a bivariate normal dis-
tribution for the pair αi and βi.
2. Model for the ξij's:
Here  is the mean ξij over studies and the 's are
constrained to keep their rank order, Δi represents the
study specific systematic deviation of the ξij's from the
overall means  and δij represents the random resid-
ual deviation of true unobserved observations. The Δi's
can be assumed to follow some parametric or non-par-
ametric distribution. In this article we assume a nor-
mal distribution given by Δi~N (0, ). The δij's are
assumed to be independent and follow a normal dis-
tribution, δij~N (0, ). Furthermore, the δij's are
assumed to be independent of the Δi and αi. The cov-
ariance between αi and Δi is denoted by σαΔ. A negative
σαΔ for instance would mean that in studies with a rel-
atively small αi the ξij's tend to be chosen relatively
high. The above assumptions (in 5 & 6) lead to the fol-
lowing marginal between-studies model:
Note that the covariance structure for the ξij's is of
compound symmetry, i.e. the between-studies vari-
ances of ξij's are assumed to be equal and the covari-
ances between any of the ξij's are assumed to be the
same. We have chosen this structure since it is popular
in repeated measures modeling as a simple but often
realistic covariance structure. Moreover the parameters
have a nice interpretation. However, one can choose
any structure. The assumption of compound symme-
try might be strong; for example, the covariance (cor-
relation) between consecutive thresholds may be
larger compared to between non-consecutive ones. If
so, a richer structure is needed. In general, the
between-studies variances and covariances of ξij's
could be allowed to be all different (unstructured cov-
ariance matrix) and, in the spirit of the general guide-
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Table 2: Two-by-three contingency table for study i for relating the FNAC outcome to the final diagnosis of breast lesion (The FNAC 
data is given in the additional file 1).
FNAC outcome Malignant Suspect Benign Total
Final diagnosis
Malignant x1i1 x1i2 x1i3 n1i
Benign x0i1 x0i2 x0i3 n0iPage 5 of 15
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BMC Medical Research Methodology 2009, 9:73 http://www.biomedcentral.com/1471-2288/9/73lines for mixed model building given by Verbeeke and
Molenberghs [23](chapter 9), it could then be simpli-
fied into another covariance structure, such as
Toeplitz, auto-regressive or compound symmetry.
Within-study model
Given (αi, β , ξi1, , ξi, J-1), the observed number of sub-
jects in the non-diseased (x0i1, , x0iJ) and diseased (x1i1,
, x1iJ) groups have independent multinomial distribu-
tions with parameters (π0i1, , π0iJ) and (π1i1, , π1iJ),
where
Note that ξij is logit(1-specificity) and ηij is logit(sensitiv-
ity) for threshold j, and the cell probabilities for diseased
(or non-diseased) subjects for category j is the difference
of sensitivities (or 1-specificities) between category j and j
- 1.
The probability density function (pdf) given the π0ij's andπ1ij's of the observations of the ith study is given by:
Inference on the parameters is obtained through the
standard likelihood method based on the marginal den-
sity for the data, which is calculated by integrating out the
random effects B = (α, ξ1, , ξJ-1)'. Then the contribution
of the ith study to the likelihood is
As seen from 7, we assumed a multivariate normal distri-
bution for the random effects. However, the density g(B)
can also be assumed to belong to some other parametric
family of distributions [24]. In summary the MREM
model allows to calculate different relevant measures of
diagnostic test accuracies:
• The mean logit sensitivity  and logit
specificity  along with their standard errors for any
known threshold, j, are estimated by the model. One
can then derive sensitivity and specificity as follows:
sensitivtyj =  and specificityj = , and the cor-
responding standard errors can be calculated using
delta method [25]. SAS NLMIXED users avoid hand
calculation by using the 'Estimate' statement (see
the SAS syntax for example).
• The diagnostic odds ratio (DOR), that can be derived
from sensitivity and specificity, for a given threshold,
j, is given by DORj = 
• The estimated parameters from model (5 - 7) are
used to derive the overall median SROC curve that is
given by sensitivity(specificity) =
. Besides, study specific ROC
curves can be generated from the empirical Bayes esti-
mates of the random effects model. In SAS NLMIXED,
the empirical Bayes estimates are generated automati-
cally and collected from the output file ('out') spec-
ified in the 'random' statement (see SAS syntax).
• Uncertainty around the SROC can be characterized
by calculating the confidence interval at each point
along the curve.
• A prediction band for the true ROC curve of a new
study can be calculated by adding and subtracting 1.96
times the estimated standard deviation of αi in the
equation above.
• The model accommodates study level covariates, for
example corresponding to two different diagnostic
tests, that enables to test the hypothesis for the differ-
ences between groups, e.g. diagnostic tests. A thor-
ough discussion of comparison between groups or test
results using the bivariate model is given in Hamza et
al [26]. In the second data example of this paper we
show how to test for the significant difference between
groups.
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BMC Medical Research Methodology 2009, 9:73 http://www.biomedcentral.com/1471-2288/9/73Fitting the model
The parameters of interest from the MREM approach ( ,
β, 's along with their between-studies variances and
covariances , σαΔ, , ,) that are used to calculate
different diagnostic test accuracy measures can be esti-
mated as follows.
1. We fitted the model using Proc NLMIXED of SAS.
This procedure does not support directly the multino-
mial distribution. However, the procedure allows a
user specified log-likelihood function. This is easily
done for the multinomial distribution. In the appen-
dix the syntax for an example is given. The NLMIXED
procedure calculates the likelihood function by
numerical integration, using adaptive Gaussian quad-
rature. The number of quadrature points is specified
by the user or automatically by SAS. The larger that
number is chosen the better the approximation, but at
the cost of more computational time. For a detailed
discussion of different choices of quadrature options,
optimization methods and convergence criteria we
refer to the SAS manual [27]. In practice, when a final
model is reached, one increases the number of quad-
rature points until the parameter estimates do not
change anymore.
2. NLMIXED allows user specified likelihoods, but
many other programs do not. Usually the binomial
distribution is supported, therefore we also mention
another possibility to fit the model in Generalized Lin-
ear Mixed Model programs. The trick is to write the
multinomial pdf as a sequence of conditional univar-
iate pdf's, i.e. the pdf of (xDi1, , xDiJ) is expressed as:
where D is the disease status, 0 or 1. These conditional
distributions are all binomial [28] and given by:
where π0ij and π1ij are calculated as in (8 & 9) with j =
1, ..., J - 1.
Results
To illustrate the methods discussed in this article, we
apply them to two published meta-analysis data-sets. One
is relatively large (29 studies) with three test result catego-
ries (2 thresholds). The second data set is small (10 stud-
ies) with five test result categories (4 thresholds). Here our
objective is to fit the models discussed in the methods sec-
tion, and to derive the SROC curves.
Example 1: Fine-needle aspiration cytologic examination
Giard and Hermans [19] present 29 studies evaluating the
accuracy of fine-needle aspiration cytologic examination
(FNAC) of the breast to assess the presence of breast can-
cer (see additional file 1. FNAC provides a non-operative
way of obtaining cells for the establishment of the nature
of a breast lump and therefore plays a pivotal role in the
preoperative diagnostic process [19,20]. The selected
FNAC results were classified in the following four cyto-
logic categories: definitely malignant, suspect for malig-
nancy, benign, and unsatisfactory specimen for diagnosis
(acellular aspiration). The last category is for those who
do not have satisfactory specimen for diagnosis. Follow-
ing the authors, we merged this group with the benign
group, which resulted in a two by three table (Table 2).
The authors [19] determined the sensitivity and specificity
of FNAC for each study by reducing the two-by-three table
into a two-by-two table. They classified malignant and
suspect test results as test result positive, and benign as test
result negative. Here, following this classification, we
applied first the BREM introduced in the method section.
The estimated median specificity and sensitivity (standard
error) are 0.927(.0015) and 0.863(0.014) respectively,
and the covariance parameters are estimated as  =
1.306(0.416), σξη = 0.139(0.156) and  =
0.317(0.105). From these estimates, the 5 different types
of SROCs were calculated and depicted in figure 1. The
corresponding intercepts and slopes, and area under the
curve (AUC) are given in table 3. Notice that there are rel-
atively large differences between these curves. As argued in
the BREM method section, from the BREM the true SROC
is not identifiable. The different curves correspond with
assuming a correlation of αi and ξij (ραξ) equal to 0.000, -
0.976, -0.400, -0.620 and -0.085 respectively for types 1 to
5 mentioned in table 1. Note that when the absolute cor-
relation increases the test accuracy as expressed by the
AUC increases. However the choice of the correlation
remains questionable and one should be careful because
it is not identifiable from the data without extra assump-
tions.
α
ξ j
σα2 σ Δ2 σδ2
p x p x x p x x xDi Di Di Di J Di Di J( ) ( | ) ( | , , ), ,1 2 1 1 1 2… …− −
x x x binomial n x
ij
ir
r
jij i i j i ir
r
j
0 0 1 0 1 0 0
1
0
1 0
1
1
| , , ~ ,,… −
=
−
−
=
−
∑
π
π
−
−
∑
⎛
⎝
⎜⎜⎜⎜⎜
⎞
⎠
⎟⎟⎟⎟⎟
−
1
1 1 1 1 1 1 1
1
x x x binomial n x
i
ij i i j i ir| , , ~ ,,…
π j
ir
r
j
r
j
1 1
1
1
1
1
−
=
−
∑
⎛
⎝
⎜⎜⎜⎜⎜
⎞
⎠
⎟⎟⎟⎟⎟=
−∑
π
σξ2
ση2Page 7 of 15
(page number not for citation purposes)
BMC Medical Research Methodology 2009, 9:73 http://www.biomedcentral.com/1471-2288/9/73
Page 8 of 15
(page number not for citation purposes)
Table 3: Parameter estimates (standard errors) and AUC of the SROC curves from the BREM and MREM approaches for the FNAC 
data
Type of SROC α β AUC
BREM
η on ξ 2.110(0.321) 0.107(0.118) 0.882
ξ on η 7.636(6.307) 2.276(2.463) 0.955
D on S 2.643(0.371) 0.316(0.137) 0.918
Rutter and Gatsonis 3.094(0.319) 0.493(0.112) 0.935
Major axis 2.191(0.406) 0.138(0.153) 0.889
MREM 2.368(0.135) 0.224(0.016) 0.902
SROC curves from the five choices of BREM approach (red = R&G, blue = D-on-S, green = Major axis, cyan = η-on-ξ and gray = ξ-on-η) and MREM approach (black) for the FNAC data setFigure 1
SROC curves from the five choices of BREM approach (red = R&G, blue = D-on-S, green = Major axis, cyan = η-
on-ξ and gray = ξ-on-η) and MREM approach (black) for the FNAC data set.
BMC Medical Research Methodology 2009, 9:73 http://www.biomedcentral.com/1471-2288/9/73Next we fitted the MREM method. The estimated median
specificities (standard error) at the first and second thresh-
olds respectively are 0.999(0.0003) and 0.928(0.018),
and the corresponding sensitivities can be estimated by
 and are 0.687(0.028)
and 0.858(0.016). Note that the estimated median specif-
icity and sensitivity at the second threshold are approxi-
mately equal to the BREM estimates. The estimated
variances and covariances were  = 0.363(0.117), σαΔ =
-0.045(0.143), σΔ = -0.042(0.443) and  =
1.841(0.615). The test for the significance of the covari-
ance between αi and ξi in the MREM approach is not sig-
nificant (likelihood ratio  = 0.999, p-value = 0.317),
and hence there is no indication for the choice of specifi-
cities to depend on the level of individual curves. The esti-
mates for the intercept and slope, and AUC are given in
table 3. The SROC from the MREM is depicted in figure 1.
Comparing the estimated SROC curves from the two
approaches, one can see that the BREM approach under-
estimates or overestimates the SROC curves depending on
the choice of the type of SROC. This can be seen clearly
from the AUC of the SROC curves in table 3. Of course, if
we had chosen another cut point for the BREM, we would
have ended up with a different SROC estimate for each of
the choices. By the delta method it is possible to construct
a confidence band for the SROC curve, as explained
above. We did not do here, to avoid a too busy picture.
In contrast to the BREM, the MREM can provide estimates
of the study specific ROCs. The program that we used,
NLMIXED from SAS, gives the empirical Bayes estimates
of the study specific random intercept αi, which enables to
draw study specific SROC curves. We give the study spe-
cific ROCs from the MREM approach in figure 2. Indeed,
the BREM can also provide study specific curves, but only
if an untestable assumption on the correlation between αi
and ξi is made. Note that the study specific curves in figure
2 are "parallel". This is because we assumed a common
fixed slope parameter β across studies. Allowing β to be
random might give study specific curves that might cross.
In principle one can do that. Then 3 extra parameters have
to be estimated: the variance of β and its covariance with
α and Δ. There are enough degrees of freedom and the
model can still be fitted in NLMIXED. However, the more
covariance parameters, the larger the chance of non-con-
vergence problems. When we tried to take β random in
this example, we were not able to get the program con-
verging, probably due to correlations becoming -1 or 1, a
phenomenon already well known in the much simpler
BREM [21].
Example 2: CAGE in screening for alcoholism
The CAGE questionnaire is a combination of four ques-
tions (resulting in a score from 0 to 4) that can be used for
the screening of patients on alcoholism or alcohol
dependence. Aertgeerts et al [22] performed a meta-analy-
sis of all published studies to evaluate the diagnostic value
of the CAGE questionnaire. In total they presented 10
studies published between January 1974 to December
2001, of which 5 were carried out in primary care popula-
tions and 5 in non-primary. In this data example we also
include the study level covariate whether or not the
patients are from primary care. If a study is carried out in
a primary care population then z1 is assigned 1 else z1 is 0.
Besides, for the MREM approach, the slope parameter is
allowed to be random and it is tested if its between-stud-
ies variance is significantly different from zero. In most
cases a CAGE score of ≥ 2 is considered to indicate an alco-
hol problem. For the illustration of the BREM method we
therefore use the threshold of ≥ 2 as test positive. Now the
mean structure in (1) or (3) is replaced by  = a0 + a1z1
and  = b0 + b1z1 [26]. The summary lines in the logit-
logit space are then y = α + γ z1 + βxb with α = b0 - a0β, γ =
(b1 - a1β)z1 and β is given by the different choices given in
table 1. The estimated parameters (standard error) are a0
= -2.135(0.390), a1 = - 0.160(0.547), b0 = 0.982(0.393)
and b1 = -0.084(0.552). The estimated specificities for
non-primary and primary care patients respectively are
0.894(0.037) and 0.908(0.032), and the corresponding
sensitivities are 0.728(0.078) and 0.711(0.080). The cov-
ariance parameters were estimated as  = 0.647(0.344),
σξη = 0.543(0.302) and  = 0.671(0.363). The resulting
estimates of the 5 lines are given in table 4 and the corre-
sponding SROCs are depicted in figure 3. Unlike the
FNAC data example, the differences between the SROC
curves are small.
The two-by-five tables from the CAGE meta-analysis were
also analyzed using the MREM approach. Here the
between-studies model in (5) can be rewritten as ηij = αi +
βiξij + γz1 to adjust for the covariate z1. Note that the slope
parameter is random and assumed to be independent of
αi and ξij; i.e. βi~N ( , ). In fact the ξij can also be
e e e ej j j jη η α βξ α βξ/( ) /( )1 1+ = ++ +
σα2
σδ2
χ12
ξ
η
σξ2
ση2
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SROC curve (black line) with 29 study specific curves (red lines) from the MREM approach for the FNAC data setFigure 2
SROC curve (black line) with 29 study specific curves (red lines) from the MREM approach for the FNAC data 
set.
Table 4: Parameter estimates (standard errors) and AUC (for non-primary care patients (non-PC), and for primary care patients 
(PC)) of the SROC curves from the BREM and MREM approaches for the CAGE data-set
Type of SROC α β γ AUCnon-PC AUCPC
BREM
η on ξ 2.775(0.712) 0.840(0.316) 0.050(0.389) 0.886 0.890
ξ on η 3.618(0.827) 1.235(0.364) 0.113(0.479) 0.902 0.908
D on S 3.160(0.710) 1.020(0.314) 0.079(0.419) 0.895 0.900
R & G 3.156(0.657) 1.019(0.286) 0.079(0.417) 0.895 0.900
Major Axis 3.165(0.776) 1.023(0.347) 0.079(0.420) 0.895 0.900
MREM 2.537(0.312) 0.795(0.047) 0.207(0.382) 0.849 0.888
BMC Medical Research Methodology 2009, 9:73 http://www.biomedcentral.com/1471-2288/9/73adjusted for study level covariates or the interaction
between ξij and z's could be added, but we did not do that
in this example. First we tested the random slope assump-
tion (  ≠ 0) with the likelihood ratio test using mixture
of chi-square test statistics. It turned out the null hypoth-
esis that the slope parameter is not random was not
rejected (p = 0.19), and therefore we fitted the MREM
model assuming fixed slope parameter. The estimated
parameter for primary versus non-primary population is
0.207(0.382), P = 0.589. Therefore there is no significant
difference between the two group of population. The esti-
mated median specificities (standard error) at thresholds
1-4 respectively are 0.994(0.002), 0.976(0.006),
0.902(0.021) and 0.742(0.045). And the estimated
median sensitivities (standard error) are 0.172(0.041),
0.403(0.068), 0.684(0.061) and 0.846(0.038) for non-
primary care patients; and 0.203(0.046), 0.453(0.069),
0.727(0.056) and 0.871(0.033) for primary care patients.
The estimated variances and covariances are  =
0.392(0.211), σαΔ = -0.217(0.178), σΔ = 0.463(0.226) and
 = 0.036(0.022). The test for the correlation between
the random intercept, αi and ξi is not significant (χ2 = 2.1,
p-value = 0.147). Therefore there is no indication for the
σ β2
σα2
σδ2
SROC curves from the five choices of BREM approach (red = R&G, blue = D-on-S, green = Major axis, cyan = η-on-ξ and gray = ξ-on-η) and MREM approach (black) for the CAGE data setFigure 3
SROC curves from the five choices of BREM approach (red = R&G, blue = D-on-S, green = Major axis, cyan = η-
on-ξ and gray = ξ-on-η) and MREM approach (black) for the CAGE data set. The curves for the primary and non-pri-
mary carry population are given in the same color but with solid and broken lines respectively. The three approaches (R&G, D 
on S and Major axis) give the same estimates (overlapped curves).Page 11 of 15
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curves. The estimated SROC parameters are given in table
4.
As shown in figure 3 and the AUCs from table 4 the bivar-
iate approach seems to over estimate the SROC curve, for
any of the 5 choices of the type of the SROC. Again this
would possibly be changed if we choose another cut-off
point for positivity on the screening test for alcoholism.
Discussion
The summary ROC curve has been introduced as a way to
assess the diagnostic accuracy of a diagnostic test in a
meta-analysis [4,5,7,29,30]. For the most frequent situa-
tion, when one point per study is presented, the medical
(and statistical) articles seem to have overlooked the
problems inherent to SROCs based on studies with only
one point. Although recent developments in the area have
shown that the bivariate random effects meta-analysis
approach has important advantages over the standard
SROC approach of Littenberg and Moses [1,2,4], the prob-
lem of identifiability and therefore interpretability of the
resulting SROC remains. When studies present more than
one point per study, commonly the test results are
reduced to two categories and meta-analysed using a well
established approach such as the BREM, which is a subop-
timal approach. In our data examples we illustrated this
by considering a single cut-off value and applying the
BREM approach. The results from the two data examples
showed that differences between the estimated SROC
curves based on the BREM approach can be large, as in the
first example, or relatively small, as in the second exam-
ple. The sizes of the differences depend on the values of
the three covariance parameters. The η on ξ and ξ on η
curves are always most extreme in the sense that the other
three lie between them. Therefore a necessary and suffi-
cient condition for the 5 different curves to be equal is the
correlation being one, which is not very probable in prac-
tical situations. Equality of the variances of ξi and ηi is a
sufficient condition for equality of the SROCs from the
three intermediate approaches (D on S, Rutter and
Gatsonis, and major axis). In the first example the vari-
ances differ a factor 4 and the correlation is relatively
small (0.22). In the second example the variances are
almost equal and the correlation is relatively large (0.82).
This explains why the differences are large in the first and
small in the second example.
In this article we generalized the BREM approach for one
threshold to the situation where more than one point per
study is available and the number of thresholds is equal
across studies. In our opinion, the MREM approach is rel-
atively easy to understand and has several advantages.
First, data of the full 2 by k table is used without losing any
information by dichotomizing the test results. Second,
different outcome measures can be derived from the fitted
model, such as SROC curves and overall sensitivity and/or
specificity for any choice of the threshold. Third, in con-
trast to the BREM approach, the summary ROC and the
study specific curves are identifiable. Fourth, the model is
symmetric in the ξij's and ηij's. Interchanging their role
leads to the same model. Fifth, it is straightforward to
include study level covariates. They can be added directly
to the intercept and slope of the SROC, and also to the
threshold values. Sixth, the MREM can be fitted in stand-
ard statistical packages without extra programming. In
equation (7), we specified compound symmetry for the
covariance structure of the ξij's. However, one can also
choose another, possibly richer structure and simplify it
using the likelihood ratio test. However, more covariance
parameters gives more risk of non-convergence problems.
For the within-study model we used the multinomial dis-
tribution instead of the summary statistic approach usu-
ally followed in meta-analysis. This avoids problems with
small numbers and zero cells are allowed.
We used NLMIXED from SAS to fit our models and
noticed that convergence of the program is sensitive for
starting values. It turned out that good starting values are
obtained by fitting the BREMs according to all possible
cut-off values.
Related work was done by Dukic and Gatsonis [12]. They
used ordinal regression and a hierarchical approach based
on latent variable modeling and fitted their model by
Bayesian methods. To our knowledge their approach is
rarely used in practice, probably due to the inherent com-
plexity of the model and fitting methods. The difference
between Dukic and Gatsonis model and the MREM is
mainly in the modeling of the ξij's. They treated them all
as fixed parameters, leading to as many ξ parameters as
there are data points, while we modeled them using the
standard multivariate meta-analysis model [13]. The
motivation for this is to reduce the number of parameters
and to correct for the measurement errors in the 's. In
our opinion, Dukic's method does not correct for meas-
urement error in the 's and leads to an inconsistent esti-
mate of the summary ROC curve, for reasons set out in
Van Houwelingen and Senn [31]. Another difference is
that Dukic's method assumes independence between the
choice of the specificities as represented by the ξij parame-
ters and the level of the study specific ROC curve as deter-
mined by αi; a not necessarily realistic assumption.
ξˆ ij
ξˆ ijPage 12 of 15
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In this paper we focused on the situation where test results
are presented with equal numbers of thresholds, but the
method is more general. In practice test results can possi-
bly be presented with different numbers of thresholds.
Often the different numbers of categories arises while all
studies in principle use the same categorization, but in dif-
ferent studies different categories are lumped together.
Then our model can still be applied without any modifi-
cation, since our approach allows missing data points.
Many other situations can be covered by allowing the
parameters of the model for the ξij's (6) to be different for
different groups of studies. For instance, suppose the goal
of the meta-analysis is to compare two tests A and B, one
with 3 and the other with 5 categories, and each study
reporting either A or B. Then the ξij model for A can be
specified to be completely different from that of B. Such a
model can still be estimated in for instance using Proc
NLMIXED. The total number of different thresholds
across all studies is the limiting factor in our approach. If
it is too large, the number of parameters might be too
large to estimate and the likelihood method may not work
properly.
Conclusion
The multivariate random effects meta-analysis approach
is an appropriate and convenient framework to meta-ana-
lyse studies with multiple threshold without losing any
information by dichotomizing the test results. The model
can be implemented on standard statistical packages.
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Appendix
SAS syntax to fit the MREM model by writing the likeli-
hood in the SAS procedure NLMIXED
*PROC NLMIXED = call SAS procedurN
LMIXEDand the options included represents:
df = degree of freedom, we specified 1000
to get Wald test in stead of t-test
qpoints = number of quadrature points, if
not specified SAS automatically does
miniter = is the minimum number of iter
ation;
PROC NLMIXED DATA = cage DF = 1000 MINITER
= 30 QPOINTS = 5;
*Specifies initial values for the maximum
likelihood estimates
if not specified, all the initial values
automatically assigned to be one;
PARMS ma = 2.6 b = 0.8 b2 = 0 mxi1 = -5.2
mxi2 = -3.7 mxi3 = -2.2 mxi4 = -1.0
va = 0.4 cavdi = -0.2 vdi = 0.5 vdij =
0.02;
*Constraint to make sure that xi's are in
the right order;
BOUNDS mxi1-mxi2< = 0, mxi2-mxi3< = 0,
mxi3-mxi4< = 0;
*Between-studies model (equation (5));
eta1 = a + b*xi1 + b2*z1;
eta2 = a + b*xi2 + b2*z1;
eta3 = a + b*xi3 + b2*z1;
eta4 = a + b*xi4 + b2*z1;
*Within-study model (equation (8));
p01 = 1/(1+exp(-(xi1)));
p02 = 1/(1+exp(-(xi2))) - 1/(1+exp(-
(xi1)));
p03 = 1/(1+exp(-(xi3))) - 1/(1+exp(-
(xi2)));
p04 = 1/(1+exp(-(xi4))) - 1/(1+exp(-
(xi3)));
p05 = 1 - 1/(1+exp(-(xi4)));Page 13 of 15
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p11 = 1/(1+exp(-(eta1)));
p12 = 1/(1+exp(-(eta2))) - 1/(1+exp(-
(eta1)));
p13 = 1/(1+exp(-(eta3))) - 1/(1+exp(-
(eta2)));
p14 = 1/(1+exp(-(eta4))) - 1/(1+exp(-
(eta3)));
p15 = 1 - 1/(1+exp(-(eta4)));
*Log-likelihood (equation (10));
if (p01^ = 0 and p02^ = 0 and p03^ = 0
and p04^ = 0 and p05^ = 0 and
p11^ = 0 and p12^ = 0 and p13^ = 0 and
p14^ = 0 and p15^ = 0) then
ll =
n01*log(p01)+n02*log(p02)+n03*log(p03)+n0
4*log(p04)+n05*log(p05)+
n11*log(p11)+n12*log(p12)+n13*log(p13)
+n14*log(p14)+n15*log(p15);
else ll = -1**100;
*SAS maximized the likelihood using the
general distribution;
MODEL n11 ~general(ll);
*Random effects parameters alpha_i and
xi_ij's are normally distributed around
their mean and between-studies variance
covariance matrix (equation 7);
RANDOM a xi1 xi2 xi3 xi4 ~normal([ma,
mxi1, mxi2, mxi3, mxi4],
[va,
cavdi, vdi+vdij,
cavdi, vdi, vdi+vdij,
cavdi, vdi, vdi, vdi+vdij,
cavdi, vdi, vdi, vdi, vdi+vdij])
SUBJECT = study OUT = study_specific;
*Empirical Bayes estimate;
*Estimate sensitivities and specificities
at each of known thresholds (1,2,3,4);
ESTIMATE 'sensitivity_1' exp(ma + mxi1)/
(1 + exp(ma + mxi1));
ESTIMATE 'sensitivity_2' exp(ma + mxi2)/
(1 + exp(ma + mxi2));
ESTIMATE 'sensitivity_3' exp(ma + mxi3)/
(1 + exp(ma + mxi3));
ESTIMATE 'sensitivity_4' exp(ma + mxi4)/
(1 + exp(ma + mxi4));
ESTIMATE 'specificity_1' exp(1)/(1 +
exp(mxi1));
ESTIMATE 'specificity_2' exp(1)/(1 +
exp(mxi2));
ESTIMATE 'specificity_3' exp(1)/(1 +
exp(mxi3));
ESTIMATE 'specificity_4' exp(1)/(1 +
exp(mxi4));
run;
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